Form 8-K CONCERT PHARMACEUTICALS, For: May 23
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- S&P 500 ends higher as markets weigh rising yields, upbeat corporate results
- Meta Platforms reports softer Q2 revenue guidance on plans to boost spending on AI
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Equities mixed as investors eye earnings; yen on intervention watch
- ServiceNow (NOW) stock falls as refreshed subscription outlook trails estimates
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Hasbro (HAS) brand strength sees earnings top expectations
- IBM (IBM) announces mixed Q1 results, HashiCorp acquisition; shares down
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
Berenberg Positive on Concert Pharmaceuticals (CNCE), 'We expect CTP-543 will be commercialized as early as H2 2023'
May 23, 2022 9:57 AM EDTBerenberg analyst Esther Hong reiterated a Buy rating and $11.00 price target on Concert Pharmaceuticals (NASDAQ: CNCE).
The analyst comments "CNCE announced positive Ph.3 data of CTP-543 in alopecia areata (AA). Today, management announced successful top-line data for the pivotal Ph.3 THRIVE-AA1 trial.... More
